Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Interleukin-12 is a heterodimeric cytokine and an important mediator of the cellular immune response. The recent discovery of the novel cytokine interleukin-23 has led to a re-evaluation of interleukin-12 biology, as both cytokines use a common p40 subunit. This review discusses understanding of what distinguishes these related cytokines and the infection risks associated with targeting these cytokine pathways during treatment of inflammatory diseases. RECENT FINDINGS: Recent work has shown that interleukin-23 stimulates the development of a distinct subset of effector T cells that produce interleukin-17A. These interleukin-17A-producing cells are critical mediators of the inflammatory response in several mouse models of autoimmunity. Although it is well established that interleukin-12 is a critical mediator of host defense, the role of the interleukin-23/interleukin-17A axis during infections has only recently been evaluated. SUMMARY: Interleukin-12 and interleukin-23 have distinct roles in mediating host defense and autoimmune inflammation. Although targeting interleukin-12 and interleukin-23 simultaneously against the common p40 subunit is efficacious in clinical trials for human autoimmune diseases, targeting of interleukin-23 alone or the downstream effector cytokine interleukin-17A may be an effective treatment strategy for organ-specific autoimmune diseases. It is likely that targeting interleukin-23 or interleukin-17A alone, as opposed to targeting interleukin-12 and interleukin-23 together, will reduce the patients' risk of developing treatment-related infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000) · Medicine · doi:10.1097/00005792-200005000-00003 · Cited by 1,728
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., & Cua, D. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030896 · Cited by 1,669
Self-citationRequirement of Interleukin‐17A for Systemic Anti– Candida albicans Host Defense in Mice
Huang, W., Na, L., Fidel, P. L., & Schwarzenberger, P. (2004) · The Journal of Infectious Diseases · doi:10.1086/422329 · Cited by 859
Cited by
Cargill, M., Schrodi, S. J., Chang, M., Garcia, V. E., Brandon, R., Callis, K. P., Matsunami, N., Ardlie, K. G., Civello, D., Catanese, J. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/511051 · Cited by 1,086
Innate lymphoid cells in the initiation, regulation and resolution of inflammation
Sonnenberg, G. F., & Artis, D. (2015) · Nature Medicine · doi:10.1038/nm.3892 · Cited by 503
Di Stefano, A., Caramori, G., Gnemmi, I., Contoli, M., Vicari, C., Capelli, A., Magno, F., D'Anna, S. E., Zanini, A., Brun, P., et al. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03965.x · Cited by 336
Sheibanie, A. F., Yen, J.-H., Khayrullina, T., Emig, F., Zhang, M., Tuma, R., & Ganea, D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.8138 · Cited by 284
Th17 T cells: Linking innate and adaptive immunity
Stockinger, B., Veldhoen, M., & Martin, B. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.10.008 · Cited by 271
Metadata
- Authors
- Bowman, E. P., Chackerian, A. A., & Cua, D. J.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2006-06
- Volume
- 19
- Issue
- 3
- Pages
- 245-252
- ISSN
- 0951-7375 (ISSN-L)
- OpenAlex
- W1978315375
- Cited by
- 58
- References
- 3
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. https://app.cochat.ai/papers/10.1097/01.qco.0000224818.42729.67
- The paper
- Bowman, E. P., Chackerian, A. A., & Cua, D. J. (2006). Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Current Opinion in Infectious Diseases. https://doi.org/10.1097/01.qco.0000224818.42729.67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.